Amikacin Inj Rx
Generic Name and Formulations:
Amikacin sulfate 100mg/2mL, 500mg/2mL, 1g/4mL; soln for IM inj or IV infusion after dilution; contains sulfites.
Various generic manufacturers
Indications for Amikacin Inj:
Short-term treatment of serious susceptible infections, including septicemia, respiratory tract, bones and joints, CNS (eg, meningitis), skin and skin structure, intra-abdominal (eg, peritonitis), burns and postoperative infections, complicated and recurrent UTIs or uncomplicated UTIs not susceptible to other antibiotics.
Give by IM inj; or IV infusion over 30–60 mins. 15mg/kg per day in 2–3 divided doses (7.5mg/kg every 12 hours or 5mg/kg every 8 hours); max 15mg/kg/day. Heavier wt. patients: max 1.5g/day. Usual duration: 7–10 days. Uncomplicated UTIs: 250mg twice daily. Renal impairment: adjust dose based on serum levels or reduce frequency; see literature.
Infants: give by IM inj; or IV infusion over 1–2 hours. Newborns: loading dose: 10mg/kg; then follow with 7.5mg/kg every 12 hours. All other children and older infants: give by IM inj; or IV infusion over 30–60 mins. 15mg/kg per day in 2–3 divided doses (7.5mg/kg every 12 hours or 5mg/kg every 8 hours); max 15mg/kg/day. Usual duration: 7–10 days. Renal impairment: adjust dose based on serum levels or reduce frequency; see literature.
Monitor for nephro- and neurotoxicity; avoid peak serum levels >35micrograms/mL and trough levels >10micrograms/mL. Discontinue or adjust dose if auditory, vestibular, or renal dysfunction develops; monitor serum levels periodically. Monitor BUN, CrCl, serum creatinine levels before, frequently during, and after therapy. Perform audiogram in high-risk patients. Maintain adequate hydration. Prolonged use or excessive doses. Asthma. Muscular disorders (eg, myasthenia gravis, parkinsonism, or infant botulism). Elderly. Premature or neonatal infants. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Avoid concomitant furosemide, ethacrynic acid. Diuretics may increase toxicity. Increased risk of neurotoxicity and/or nephrotoxicity with concurrent or sequential polymyxin B, colistin, amphotericin B, other nephrotoxic or neurotoxic drugs; avoid. May potentiate neuromuscular blockade, respiratory paralysis with anesthetics, neuromuscular blockers. May be antagonized by concomitant penicillins, cephalosporins.
Nephrotoxicity (eg, azotemia, oliguria), ototoxicity, neurotoxicity, neuromuscular blockade (eg, muscular paralysis, apnea); rare: rash, drug fever, headache, tremor, GI upset, paresthesia, eosinophilia, arthralgia, anemia, hypotension, hypomagnesium.
Formerly known under the brand name Amikin.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy